| Literature DB >> 25175155 |
Henry Jensen1, Marie Louise Tørring, Frede Olesen, Jens Overgaard, Peter Vedsted.
Abstract
BACKGROUND: Many countries have implemented standardised cancer patient pathways (CPPs) to ensure fast diagnosis of patients suspected of having cancer. Yet, studies are sparse on the impact of such CPPs, and few have distinguished between referral routes. For incident cancer patients, we aimed to determine how often GPs suspected cancer at the time of first presentation of symptoms in general practice and to describe the routes of referral for further investigation. In addition, we aimed to analyse if the GP's suspicion of cancer could predict the choice of referral to a CPP. Finally, we aimed to analyse associations between not only cancer suspicion and time to cancer diagnosis, but also between choice of referral route and time to cancer diagnosis.Entities:
Mesh:
Year: 2014 PMID: 25175155 PMCID: PMC4164756 DOI: 10.1186/1471-2407-14-636
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Figure 1Flowchart showing patient inclusion. Boxes on the left indicate exclusion of patients, while boxes on the right indicate drop-outs.
Characteristics of included patients for whom the GP was involved in the clinical pathway, shown by cancer site and total (N = 3,823)
| Colorectal | Lung | Malignant melanoma | Breast | Prostate | Other | Total | |
|---|---|---|---|---|---|---|---|
| n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | |
|
| 612(100) | 474(100) | 227(100) | 518(100) | 556(100) | 1,436(100) | 3,823(100) |
|
| |||||||
| Male | 325(53.1) | 266(56.1) | 100(44.1) | 0(0) | 556(100) | 790(55.0) | 2,037(53.3) |
| Female | 287(46.9) | 208(43.9) | 127(55.9) | 518(100) | 0(0) | 646(45.0) | 1,786(46.7) |
|
| |||||||
| 18-44 | 16(2.6) | 3(0.6) | 63(27.8) | 69(13.3) | 0(0) | 146(10.2) | 297(7.8) |
| 45-54 | 46(7.5) | 42(8.9) | 48(21.1) | 119(23.0) | 20(3.6) | 184(12.8) | 459(12.0) |
| 55-64 | 115(18.8) | 136(28.7) | 43(18.9) | 100(19.3) | 136(24.5) | 325(22.6) | 855(22.4) |
| 65-74 | 219(35.8) | 167(35.2) | 36(15.9) | 91(17.6) | 238(42.8) | 400(27.9) | 1,151(30.1) |
| > = 75 | 216(35.3) | 126(26.6) | 37(16.3) | 139(26.8) | 162(29.1) | 381(26.5) | 1,061(27.8) |
|
| |||||||
| Alarm | 298(48.7) | 148(31.2) | 121(53.3) | 419(80.9) | 264(47.5) | 592(41.2) | 1,842(48.2) |
| Serious | 127(20.8) | 162(34.2) | 9(4.0) | 27(5.2) | 59(10.6) | 362(25.2) | 746(19.5) |
| Vague | 187(30.6) | 164(34.6) | 97(42.7) | 72(13.9) | 233(41.9) | 482(33.6) | 1,235(32.3) |
|
| |||||||
| Cancer Patient Pathway (CPP) | 222(36.3) | 193(40.7) | 82(36.1) | 324(62.5) | 220(39.6) | 385(26.8) | 1,426(37.3) |
| Cancer obs – no CPP | 108(17.6) | 79(16.7) | 76(33.5) | 92(17.8) | 199(35.8) | 369(25.7) | 923(24.1) |
| Other | 262(42.8) | 174(36.7) | 61(26.9) | 83(16.0) | 114(20.5) | 613(42.7) | 1,307(34.2) |
| Unknown | 20(3.3) | 28(5.9) | 8(3.5) | 19(3.7) | 23(4.1) | 69(4.8) | 167(4.4) |
|
| |||||||
| None | 453(74.0) | 323(68.1) | 192(84.6) | 406(78.4) | 422(75.9) | 1,088(75.8) | 2,884(75.4) |
| Moderate | 132(21.6) | 124(26.2) | 33(14.5) | 93(18.0) | 114(20.5) | 286(19.9) | 782(20.5) |
| High | 27(4.4) | 27(5.7) | 2(0.9) | 19(3.7) | 20(3.6) | 62(4.3) | 157(4.1) |
| Missing | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) | 0(0) |
|
| |||||||
| Low | 237(38.7) | 211(44.5) | 61(26.9) | 179(34.6) | 182(32.7) | 551(38.4) | 1,421(37.2) |
| Medium | 230(37.6) | 170(35.9) | 93(41.0) | 202(39.0) | 236(42.4) | 558(38.9) | 1,489(38.9) |
| High | 112(18.3) | 73(15.4) | 67(29.5) | 121(23.4) | 126(22.7) | 263(18.3) | 762(19.9) |
| Missing | 33(5.4) | 20(4.2) | 6(2.6) | 16(3.1) | 12(2.2) | 64(4.5) | 151(3.9) |
|
| |||||||
| Low | 233(38.1) | 198(41.8) | 50(22.0) | 150(29.0) | 138(24.8) | 494(34.4) | 1,263(33.0) |
| Medium | 209(34.2) | 161(34.0) | 73(32.2) | 184(35.5) | 194(34.9) | 481(33.5) | 1,302(34.1) |
| High | 169(27.6) | 115(24.3) | 103(45.4) | 183(35.3) | 224(40.3) | 460(32.0) | 1,254(32.8) |
| Missing | 1(0.2) | 0(0) | 1(0.4) | 1(0.2) | 0(0) | 1(0.1) | 4(0.1) |
|
| |||||||
| North Denmark Region | 61(10.0) | 43(9.1) | 24(10.6) | 60(11.6) | 81(14.6) | 178(12.4) | 447(11.7) |
| Central Denmark Region | 141(23.0) | 120(25.3) | 48(21.1) | 129(24.9) | 148(26.6) | 343(23.9) | 929(24.3) |
| Region of Southern Denmark | 139(22.7) | 101(21.3) | 86(37.9) | 128(24.7) | 112(20.1) | 321(22.4) | 887(23.2) |
| Capital Region of Denmark | 142(23.2) | 128(27.0) | 53(23.3) | 109(21.0) | 130(23.4) | 359(25.0) | 921(24.1) |
| Region Zealand | 129(21.1) | 82(17.3) | 16(7.0) | 92(17.8) | 85(15.3) | 235(16.4) | 639(16.7) |
1Charlson’s Comorbidity index, 2ISCED = International Standard Classification of Education, 3Disposable income (in thousand of euro according to OECD classification, 4Region of the patient’s GP as of November 2010.
Number and percentages of Cancer Patient Pathways (CPP) used among patients for whom the GP was involved in the diagnosis, shown by cancer site and total (N = 1,426)
| Colorectal | Lung | Malignant melanoma | Breast | Prostate | Other | Total | |
|---|---|---|---|---|---|---|---|
| n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | n(%) | |
|
| 222(36.3) | 193(40.7) | 82(36.1) | 324(62.5) | 220(39.6) | 385(26.8) | 1,426(37.3) |
|
| |||||||
| Male | 130(40.0) | 110(41.4) | 38(38.0) | 0(0) | 220(39.6) | 230(29.1) | 728(35.7) |
| Female | 92(32.1) | 83(39.9) | 44(34.6) | 324(62.5) | 0(0) | 155(24.0) | 698(39.1) |
|
| |||||||
| 18-44 | 6(37.5) | 1(33.3) | 22(34.9) | 37(53.6) | 0(0) | 39(26.7) | 105(35.4) |
| 45-54 | 12(26.1) | 13(31.0) | 15(31.3) | 67(56.3) | 10(50.0) | 53(28.8) | 170(37.0) |
| 55-64 | 50(43.5) | 58(42.6) | 20(46.5) | 62(62.0) | 58(42.6) | 87(26.8) | 335(39.2) |
| 65-74 | 82(37.4) | 74(44.3) | 14(38.9) | 55(60.4) | 104(43.7) | 102(25.5) | 431(37.4) |
| > = 75 | 72(33.3) | 47(37.3) | 11(29.7) | 103(74.1) | 48(29.6) | 104(27.3) | 385(36.3) |
|
| |||||||
| Alarm | 163(54.7) | 74(50.0) | 51(42.1) | 305(72.8) | 121(45.8) | 243(41.0) | 957(52.0) |
| Serious | 17(13.4) | 52(32.1) | 0(0) | 5(18.5) | 20(33.9) | 55(15.2) | 149(20.0) |
| Vague | 42(22.5) | 67(40.9) | 31(32.0) | 14(19.4) | 79(33.9) | 87(18.0) | 320(25.9) |
Patient’s chance of CPP referral initiated by the GP, expressed as adjusted prevalence ratios (PRs) by cancer site and total (N=3,672)
| Colorectal | Lung | Malignant melanoma | Breast | Prostate | Other | Total | |
|---|---|---|---|---|---|---|---|
| PRR (95% CI) | PRR (95% CI) | PRR (95% CI) | PRR (95% CI) | PRR (95% CI) | PRR (95% CI) | PRR (95% CI) | |
|
| |||||||
| Male | 1.08(0.88-1.32) | 1.02(0.81-1.27) | 1.02(0.72-1.44) | n/a | 1.00 |
|
|
| Female | 1.00(ref) | 1.00(ref) | 1.00(ref) | 1.00 | n/a | 1.00(ref) | 1.00(ref) |
|
| |||||||
| 18-44 | 1.67(0.87-3.18) | 0.64(0.09-4.32) | 1.16(0.60-2.21) | 0.86(0.69-1.09) |
| 0.98(0.71-1.34) | 1.04(0.88-1.24) |
| 45-54 | 1.02(0.63-1.66) | 0.72(0.43-1.22) | 1.09(0.54-2.19) |
| 1.70(0.98-2.93) | 1.04(0.78-1.39) | 0.97(0.84-1.12) |
| 55-64 |
| 0.94(0.68-1.29) | 1.69(0.88-3.26) |
| 1.33(0.96-1.83) | 1.05(0.82-1.36) | 1.11(0.98-1.26) |
| 65-74 | 1.18(0.91-1.54) | 1.09(0.83-1.42) | 1.39(0.72-2.68) | 0.88(0.72-1.07) |
| 0.92(0.72-1.17) | 1.06(0.95-1.18) |
| > = 75 | 1.00(ref) | 1.00(ref) | 1.00(ref) | 1.00(ref) | 1.00(ref) | 1.00(ref) | 1(ref) |
|
| |||||||
| Alarm | 1.00(ref) | 1.00(ref) | 1.00(ref) | 1.00(ref) | 1.00(ref) | 1.00(ref) | 1.00(ref) |
| Serious |
|
| n/a |
| 0.71(0.47-1.06) |
|
|
| Vague |
| 0.83(0.65-1.05) | 0.76(0.52-1.13) |
|
|
|
|
Adjusted for the patient’s gender, age, co-morbidity, educational background and disposable income, cancer site and patient clusters at GP level.
Estimates marked in bold were statistically significant at minimum level of p < 0.05.
n/a = not applicable.
Unadjusted median diagnostic intervals (DIs) with inter-quartile intervals (IQI) displayed for five high incidence cancer sites and totally (N=3,823)
| Colorectal | Lung | Malignant melanoma | Breast | Prostate | Other | Total | |
|---|---|---|---|---|---|---|---|
| Median (IQI) | Median (IQI) | Median (IQI) | Median (IQI) | Median (IQI) | Median (IQI) | Median (IQI) | |
|
| 31(14;69) | 28(11;67) | 28(12;55) | 18(8;34) | 46(21;110) | 40(16;88) | 32(14;73) |
|
| |||||||
| Male |
| 27(9;67) | 22(9;53) | n/a | 46(21;110) | 38(15;84) |
|
| Female |
| 28(13;69) | 30(15;56) | 18(8;34) | n/a | 43(17;90) |
|
|
| |||||||
| 18-44 | 44(31;89) |
| 31(11;55) | 19(11;30) | n/a | 45(15;116) |
|
| 45-54 | 31(16;61) |
| 23(12;45) | 22(8;36) | 47(25;160) | 35(16;73) |
|
| 55-64 | 28(11;67) |
| 24(11;45) | 15(6;32) | 36(22;105) | 38(15;77) |
|
| 65-74 | 30(14;61) |
| 30(15;56) | 21(9;36) | 46(22;97) | 41(17;90) |
|
| > = 75 | 34(15;83) |
| 36(14;68) | 14(7;30) | 53(17;165) | 42(14;94) |
|
|
| |||||||
| Alarm |
|
|
|
|
|
|
|
| Serious |
|
| n/a |
|
|
|
|
| Vague |
|
|
|
|
|
|
|
|
| |||||||
| Cancer Patient Pathway (CPP) |
|
|
|
|
|
|
|
| Cancer obs – no CPP |
|
|
|
|
|
|
|
| Other |
|
|
|
|
|
|
|
| Unknown |
|
|
|
|
|
|
|
Estimates marked in bold were statistically significant at minimum level of p < 0.05.
n/a = not applicable.
Diagnostic interval in calendar days displayed by GP’s symptom interpretation, referral mode, gender, age groups and co-morbidity (N=3,672)
| Quantile regression results (adjusted) 1 | |||||
|---|---|---|---|---|---|
| 25th percentile | 50th percentile | 75th percentile | 90th percentile | ||
| n (%) | estimate (95% CI) | estimate (95% CI) | estimate (95% CI) | estimate (95% CI) | |
|
| |||||
| Male | 1,961 (53.4) |
| -1(-6;3) | -6(-21;10) | -19(-242;203) |
| Female | 1,711 (46.6) | ref. | ref. | ref. | ref. |
|
| |||||
| 18-44 | 289 (7.9) | -1(-7;4) | -1(-9;4) | -8(-22;7) | -52(-139;35) |
| 45-54 | 447 (12.2) | -2(-6;2) | -6(-12;0) | -10(-25;5) | -37(-276;303) |
| 55-64 | 835 (22.7) |
| -5(-10;1) | -11(-29;7) |
|
| 65-74 | 1,129 (30.7) | 0(-2;2) | 0(-6;6) | -2(-21;17) | -30(-107;48) |
| > = 75 | 972 (26.5) | ref. | ref. | ref. | ref. |
|
| |||||
| Alarm | 1,766 (48.1) | ref. | ref. | ref. | ref. |
| Serious | 706 (19.2) |
|
|
| 68(-102;237) |
| Vague | 1,200 (32.7) |
|
|
| 192(-98;483) |
|
| |||||
| CPP | 1,371 (37.3) | ref. | ref. | ref. | ref. |
| Cancer obs. – no CPP | 888 (24.2) |
|
|
| 108(-31;248) |
| Other reasons | 1,253 (34.1) |
|
|
| 123(86;331) |
| Unknown | 160 (4.4) | 3(-7;13) | 10(-10;30) |
| 179(-412;770) |
|
| |||||
| None | 2,780 (75.7) | ref. | ref. | ref. | ref. |
| Moderate | 741 (20.2) | -1(-3;1) | 2(-2;7) | 8(-6;23) | 5(-57;66) |
| High | 151 (4.1) | -2(-7;4) | 1(-9;13) | -1(-30;28) | -27(-110;55) |
Point estimates marked in bold are statistically significant at minimum level of p < 0.05.
1Adjusted for gender, age groups, symptom interpretation, referral mode, cancer site, comorbidity, educational background, disposable income and region of residence.